Posts

FDA Approves Merck's Once-Daily HIV Pill Idvynso (Doravirine/Islatravir)

The U.S. FDA approved Merck's once-daily oral two-drug combination of doravirine (100 mg) and islatravir (0.25 mg), branded as Idvynso, for treating HIV-1 in virologically suppressed adults as a regimen switch. 1 3 4 Approval announced on April 21, 2026, supported by Week 48 data from Phase 3 trials MK-8591A-051 and MK-8591A-052 involving 708 participants. 4 5 In Trial 052, 1% of Idvynso switchers had viral load ≥50 copies/mL at Week 48 vs. 1% on Biktarvy; in Trial 051, 1% vs. 5% on baseline therapy. 4 Doravirine is already approved as Pifeltro; islatravir is investigational; regimen is non-inferior to three-drug standards without an integrase inhibitor. 1 5 Sources: 1. https://www.marketscreener.com/news/us-fda-approves-merck-s-combination-hiv-treatment-ce7f59dbdd8af526 3. https://www.investing.com/news/stock-market-news/us-fda-approves-mercks-combination-hiv-treatment-4626858 4. https://au.investing.com/news/company-news/fda-approves-mercks-idvynso-for-hiv1-treatmen...

Trump Administration Indefinitely Delays Medicare Weight-Loss Drug Pilot Program

Roche's Fenebrutinib Delays MS Relapses in Phase 3 Trials but Faces Liver Toxicity and Safety Scrutiny

ImmunoForge Accelerates CNS Drug Development with Innovative BBB Shuttle Platform LMT15

Sage Alumni Launch Tortugas with $106M to Advance CNS Pipeline

AstraZeneca's Ultomiris Meets Primary Endpoint in Phase III IgAN Trial, Reducing Proteinuria

Zephyr AI Appoints Dr. Lisa Eli as Chief Scientific Officer

MyOme Strengthens Board with Appointment of Two Healthcare Leaders

Biopharma Companies Encounter AI's Weak Spot: Scientific Context, Says Zifo

NIH-Funded scSurvival AI Model Predicts Cancer Survival from Single-Cell Tumor Data

NOVI Health's Hybrid Care Model Matches Clinical Trial GLP-1 Weight Loss in Real-World Asian Study

Flagship Pioneering Launches Serif Biomedicines with $50M for DNA Medicines

Merck Litespark Shocker: Welireg Triplet Fails in First-Line Kidney Cancer